Kuros Biosciences
-
Biologics
Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH
SCHLIEREN (ZURICH), Switzerland, Sept. 01, 2020 (GLOBE NEWSWIRE) — Kuros Biosciences, a leader in next generation bone graft technologies, today announced…
Read More » -
Biologics
Kuros Biosciences Reports Results for First Half 2020
ZURICH, Switzerland, Aug. 12, 2020 (GLOBE NEWSWIRE) — Kuros Biosciences, a leader in next generation bone graft technologies, today reported…
Read More » -
Biologics
Kuros Biosciences Further Strengthens Orthobiologics Patent Portfolio
SCHLIEREN (ZURICH), Switzerland, July 22, 2020 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros…
Read More » -
Biologics
Kuros Reports Publication of MagnetOs Preclinical Data Demonstrating Superiority to Market-Leading Synthetic Bone Grafts in Spinal Fusion
SCHLIEREN (ZURICH), Switzerland, Jan. 30, 2020 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) today announced the publication of data from…
Read More » -
Biologics
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion
Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to autograftPrimary endpoint is radiographic interbody fusion at 12 months SCHLIEREN…
Read More » -
Financial
Kuros Biosciences Reports Results for First Half 2019
Financial highlights CHF 13.4 million cash and cash equivalents (including trade and other receivables) at June 30, 2019Product sales were…
Read More » -
Biologics
Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia and New Zealand
Kuros expands distribution of MagnetOs to Australia and New ZealandFirst sale of MagnetOs in Australia expected in 2020 SCHLIEREN (ZURICH),…
Read More » -
Biologics
Kuros Biosciences to propose re-appointment of Chairman and Board Members at Annual General Meeting
Schlieren (Zurich), Switzerland, April 30, 2019 – Kuros Biosciences (SIX: KURN) will propose the re-appointment of Clemens van Blitterswijk as…
Read More » -
Financial
Kuros Biosciences Enters Convertible Bond Financing Agreement For Up To CHF 5 Million
SCHLIEREN (ZURICH), Switzerland, April 09, 2019 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) today announced that it has entered into…
Read More » -
Regulatory
Kuros Biosciences Receives US Marketing Clearance for Intervertebral Body Fusion Device
SCHLIEREN (ZURICH), Switzerland, March 13, 2019 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros…
Read More » -
Biologics
Kuros Biosciences Signs Agreement to Supply SeaSpine with Bone Graft Incorporating Kuros’s Advanced Submicron Surface Technology
SCHLIEREN (ZURICH), Switzerland, Feb. 11, 2019 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros…
Read More » -
Biologics
Kuros Ends Transformational Year With First MagnetOs Sales, Lead Clinical Program on Track, and Successful Capital Raise
SCHLIEREN (ZURICH), Switzerland, Dec. 17, 2018 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) has completed a transformational year, having realized…
Read More » -
Biologics
Kuros Reports Publication of MagnetOs Data Demonstrating Equivalence to Autologous Bone in Spinal Fusion
SCHLIEREN (ZURICH), Switzerland, Dec. 06, 2018 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) today announced the publication of data from…
Read More » -
Biologics
Kuros Biosciences Advances its Fibrin-PTH (KUR-113) Spinal Fusion Product Candidate Program
SCHLIEREN (ZURICH), Switzerland, Oct. 18, 2018 (GLOBE NEWSWIRE) — Kuros Biosciences AG (SIX: KURN) announced today that the Company has reached…
Read More » -
Spine
Kuros Reports First Patient Treated in Randomized Controlled Trial of MagnetOs in Spinal Fusion
SCHLIEREN (ZURICH), Switzerland, Sept. 27, 2018 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) today announced that the first patient has…
Read More »